Replies to post #124074 on Biotech Values

[DewDiligence]

If HCV were the primary driver of Promacta sales I would look for them to raise their pricing.

I don’t think HCV will be a major portion of Promacta sales, so it may not be advisable to raise the price to coincide with the shortened average duration of interferon usage. It’s a Catch-22.